Understanding the Types of Trials Currently Running
The UK Severe Asthma Registry, known as UKSAR, has been producing research that directly shapes how biologics are prescribed. One study published in mid-2025 examined what happens when patients with severe asthma are assessed for adherence before starting a biologic treatment. The findings highlighted something clinicians had long suspected: a meaningful number of people who appeared to have treatment-resistant asthma were simply not using their prescribed inhalers consistently. By identifying this early, specialists could avoid escalating patients to expensive injectable medications unnecessarily. This kind of research is not just academic; it changes what happens in consultant appointments across the NHS.
Other trials focus on digital interventions. Researchers at the University of Oxford are leading a randomised controlled trial that recruits adults from GP asthma registers in multiple UK regions, including areas of England and Scotland. Participants attend a one-off face-to-face appointment with a primary care healthcare professional and are then followed up every three months over a full year. The intervention being tested is a digital social support tool designed to improve asthma control. What makes this study particularly interesting is its pragmatic design: it runs within real general practices rather than specialist research centres, meaning the results will reflect what actually happens in everyday NHS settings.
For those with milder or moderate asthma, there are studies evaluating newer formulations of established medications. A recent cost-effectiveness analysis looked at single-inhaler triple therapy using extra-fine beclometasone, formoterol, and glycopyrronium for adults with uncontrolled asthma in England. The research concluded that this approach could reduce healthcare spending while maintaining equivalent clinical outcomes compared with other triple therapy regimens. Studies like this matter because they provide the evidence base that NICE uses to decide which treatments should be routinely available.
What the Experience Actually Involves
People often imagine clinical trials mean long hospital stays and endless needles. The reality is usually far less dramatic. Most asthma studies in the UK are outpatient-based. You might attend a screening visit where your lung function is measured with spirometry, answer questionnaires about your symptoms and quality of life, and then receive either the study treatment or standard care depending on how the trial is designed. Follow-up visits happen at intervals, often every few months, and many studies now incorporate remote check-ins by phone or through apps.
Take the example of Claire, a 42-year-old teacher from Manchester who enrolled in an asthma biologic study after years of repeated oral steroid courses. She described the process as more straightforward than she expected. "I thought I would feel like a guinea pig, but actually the research nurse spent more time explaining things than my regular consultant ever had. I got a lung function test done properly for the first time in years, and the travel expenses were reimbursed each visit." Her experience mirrors what many participants report: the additional monitoring and attention that comes with being in a trial can be valuable even aside from the treatment being studied.
The ethical framework governing UK trials is robust. Every study must receive approval from an NHS Research Ethics Committee before it can begin recruiting. Participants give written informed consent and can withdraw at any time without their usual NHS care being affected. The General Data Protection Regulation applies throughout, and anonymised data is used in any published results.
A Closer Look at Available Study Categories
Below is a breakdown of the main types of asthma trials currently recruiting or recently completed across the UK, along with the kinds of patients each is suited to.
| Trial Category | Example Focus | Typical Duration | Suitable For | Key Benefit | Potential Drawback |
|---|
| Biologic therapy studies | Mepolizumab, benralizumab, dupilumab | 12–24 months | Severe eosinophilic or allergic asthma | Access to specialist monitoring | Requires regular injections |
| Digital health interventions | App-based symptom tracking, social support tools | 6–12 months | Mild to moderate asthma | Minimal time commitment | May not suit those uncomfortable with technology |
| Inhaler device comparisons | Triple therapy in single device vs multiple | 12–52 weeks | Uncontrolled moderate asthma | Simplified treatment regimen | Placebo arm possible in some studies |
| Lifestyle and behavioural | Breathing exercises, dietary interventions | 3–6 months | All asthma severities | Non-pharmacological approach | Effects may be modest |
| Paediatric studies | Early intervention in wheeze, prevention trials | 1–5 years | Children aged 0–16 | Specialised paediatric monitoring | Parental consent and involvement required |
The table above reflects the diversity of what is currently available. The digital intervention study recruiting through GP practices, for instance, suits adults who might not consider themselves "trial participants" in the traditional sense. You simply receive access to a tool designed to support self-management, and your progress is tracked through routine data. Meanwhile, biologic studies tend to be hospital-based and involve more intensive monitoring, but they also offer the potential for significant symptom improvement in people who have exhausted standard treatment options.
Finding a Trial Near You
The most straightforward starting point is the Be Part of Research website, run by the National Institute for Health and Care Research, which lists studies recruiting across England. You can filter by location and condition. For those in Scotland, NHS Research Scotland provides a similar service, while Health and Care Research Wales covers Welsh sites.
Your GP or asthma nurse can also point you towards relevant studies. Many general practices are part of the Clinical Research Network and receive notifications when trials are recruiting locally. If you are under a hospital consultant for severe asthma, asking at your next outpatient appointment is often the most direct route, as many biologic trials recruit exclusively through secondary care.
Asthma + Lung UK, formed through the merger of Asthma UK and the British Lung Foundation, maintains research listings and patient information resources. Their research output spans health sciences and public health, and they have a track record of funding studies that address the questions patients themselves prioritise. Browsing their website can give you a sense of what kinds of research are currently active.
Before contacting a research team, it helps to have a clear picture of your own asthma history: what medications you take, how often you need reliever inhalers, whether you have had courses of oral steroids in the past year, and any hospital admissions. This information helps the research team quickly assess whether you might fit the eligibility criteria for their specific study.
What if a trial is not right for you right now? That is a perfectly valid conclusion. Many people decide the time commitment does not suit their schedule, or they prefer to stick with their established treatment. The Asthma + Lung Foundation partnership also runs surveys and registry programmes that allow patients to contribute to research without enrolling in interventional studies. These lighter-touch options still move the science forward and can be a good way to engage with research on your own terms.
The UK research infrastructure means that participating in a clinical trial is generally a well-supported experience. Travel costs are routinely reimbursed, appointments are arranged around work and family commitments where possible, and the level of clinical monitoring is high. The decision to enrol should always be made after careful discussion with the research team and, ideally, with input from your regular healthcare provider. But for many people living with asthma, especially those whose symptoms remain troublesome despite treatment, clinical trials represent a genuine opportunity to try something different while helping to build the evidence that will guide care for years to come.
研究の知恵